Albireo to Report Q4 and Year-End 2020 Financial Results on February 25
February 18 2021 - 7:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that management will host a conference
call and live audio webcast at 10:00 a.m. ET on February
25, 2021, to provide a business update and review the company’s
financial results for the fourth quarter and year ended December
31, 2020.
To access the live conference call by phone, please dial
877-407-0792 (domestic) or 201-689-8263 (international), and
provide the access code 13715566. A live audio webcast will be
accessible from the Media & Investors page of Albireo’s
website, https://ir.albireopharma.com/. To ensure a timely
connection to the webcast, it is recommended that users register at
least 15 minutes prior to the start time. An archived version of
the webcast will be available for replay in the Events &
Presentations section of the Media & Investors page of
Albireo’s website for 3 months following the event.
About AlbireoAlbireo Pharma is a clinical-stage
biopharmaceutical company focused on the development of novel bile
acid modulators to treat rare pediatric and adult liver diseases.
Albireo’s lead product candidate, odevixibat, is being developed to
treat rare pediatric cholestatic liver diseases with Phase 3
pivotal trials in PFIC, Alagille syndrome and biliary atresia. The
Company completed IND-enabling studies for new preclinical
candidate A3907 and plans to advance development in adult liver
disease. Albireo was spun out from AstraZeneca in 2008 and is
headquartered in Boston, Massachusetts, with its key operating
subsidiary in Gothenburg, Sweden. The Boston Business
Journal named Albireo one of the 2020 Best Places to Work
in Massachusetts for the second consecutive year. For more
information on Albireo, please
visit www.albireopharma.com.
Media Contact:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLisa Rivero,
617-947-0899, lisa.rivero@syneoshealth.com
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2024 to May 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From May 2023 to May 2024